US EditionPublished • loading... • Updated
Altimmune, Inc. (ALT) Stock Analysis: Exploring A 366% Potential Upside In Biotech Innovation
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Altimmune, Inc. (ALT) Stock Analysis: Exploring A 366% Potential Upside In Biotech Innovation
Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical company, stands at a fascinating juncture with a compelling potential upside of 366.12%. As a player in the biotechnology sector, Altimmune focuses on developing innovative treatments for obesity, metabolic, and liver diseases. Its lead candidate, pemvidutide, shows promise in addressing these critical health issues and is currently in Phase 3 trials. The company, founded in 1997 …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
